Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as unlimited liability partner, has made a new investment in Perseus Proteomics Inc. (Head office: Meguro-ku, Tokyo; Representative Director: Takuya Yokogawa).

Outline of this investment
Perseus Proteomics is a drug discovery venture established based on research results from the University of Tokyo's Center for Advanced Science and Technology, and its main business is the practical application of antibody drugs. Perseus Proteomics has jointly applied for patents in collaboration with Kyoto University, and Professor Fuyuki Ishikawa of the Graduate School of Life Sciences serves as a scientific advisor to the company.

Perseus Proteomics' development pipeline includes PPMX-T001, an anti-GPC3 antibody, and PPMX-T002, an anti-cadherin antibody, both of which have reached Phase 2. PPMX-T003, a unique antibody targeting transferrin, is in development for the treatment of refractory true polycythemia vera and is currently in Phase 1.

Perseus Proteomics possesses proprietary protein expression and antibody production technologies, and has established a system capable of producing antibodies with high affinity for a variety of proteins. Kyoto iCAP has invested 100 million yen in Perseus Proteomics in recognition of the company's advanced technological capabilities. In addition to the KYOTO-iCAP No. 1 Fund, other investors include DBJ Capital Investment Limited Partnership, SBI4&5 Investment Limited Partnership, M3 Corporation, Axil Life Science & Healthcare Fund No. 1 Investment Limited Partnership, and SBI4&5 Investment Limited Partnership. & Healthcare Fund No.1 Investment Limited Partnership, GA No.3 Investment Limited Partnership, and GA No.4 Investment Limited Partnership.

Outline of Perseus Proteomics Inc.

Establishment	February 2001
Business	Development of antibody drugs and novel diagnostic methods utilizing antibodies
Head Office Location	Meguro-ku, Tokyo
President & CEO	Takuya Yokogawa